journal article·2010-09-01

Solid State Forms of Theophylline: Presenting a New Anhydrous Polymorph

Linda Seton, Dikshitkumar Khamar, Ian J. Bradshaw, Gillian A. Hutcheon

Crystal Growth & Design· Volume 10· Issue 9
Publisher page

Abstract

A previously unreported anhydrous polymorph (Form IV) of theophylline has been crystallized and characterized. Solubility determination, crystallization, and equilibration experiments indicated that Form IV is the most thermodynamically stable anhydrous polymorph. The hydration behavior of theophylline was investigated by three different methods: solubility, crystallization, and slurry experiments. The value of water activity at which the monohydrate form of theophylline becomes the most thermodynamically stable was investigated, and these results help to explain differences reported in the literature. Using solvent mixtures with a range of water activity values, it was demonstrated that the monohydrate, Form M, is produced from mixtures with a w ≥ 0.70 at 25 °C.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Crystallization and Solubility Studies · Thermal and Kinetic Analysis · Inorganic and Organometallic Chemistry

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 3AF, U.K.

References (23)

Show source-provided references
1. Trask A. V. · Int. J. Pharm. · 2006 · 320 · 11410.1016/j.ijpharm.2006.04.018 ↗
2. Karki S. · Mol. Pharmaceutics · 2007 · 4 · 34710.1021/mp0700054 ↗
3. Wikstroem H. · Cryst. Growth Des. · 2008 · 8 · 268410.1021/cg070629e ↗
4. Amado A. M. · J. Pharm. Sci. · 2007 · 96 · 136610.1002/jps.20923 ↗
5. Gould P. L. · Int. J. Pharm. · 1989 · 51 · 19510.1016/0378-5173(89)90192-0 ↗
6. Shefter, E.; Higuchi, T.J. Pharm. Sci. 1963, 52.10.1002/jps.2600520815 ↗
7. Sun C. Q. · Acta Crystallogr., Sect. E: Struct. Rep. Online · 2002 · 58 · O36810.1107/S1600536802002921 ↗
8. Matsuo K. · Cryst. Growth Des. · 2007 · 7 · 41110.1021/cg060299i ↗
9. Phadnis N. V. · J. Pharm. Sci. · 1997 · 86 · 125610.1021/js9701418 ↗
10. Zhu H. J. · Int. J. Pharm. · 1996 · 135 · 15110.1016/0378-5173(95)04466-3 ↗
11. Ticehurst M. D. · Int. J. Pharm. · 2002 · 247 · 110.1016/S0378-5173(02)00277-6 ↗
12. Sutor D. J. · Acta Crystallogr. · 1958 · 11 · 8310.1107/S0365110X58000232 ↗
13. Mercury, Crystal structure visualization program, version 2.2;The Cambridge Crystallographic Data Centre,Cambridege, U.K., 2008.
14. Ebisuzaki Y. · Acta Crystallogr., Sect. C: Cryst. Struct. Commun. · 1997 · 53 · 77710.1107/S0108270197001960 ↗
15. Suzuki E. · Chem. Pharm. Bull. · 1989 · 37 · 49310.1248/cpb.37.493 ↗
16. Otsuka M. · J. Pharm. Pharmacol. · 1990 · 42 · 60610.1111/j.2042-7158.1990.tb06616.x ↗
17. Smith E. D. L. · J. Phys. Chem. B · 2001 · 105 · 581810.1021/jp002060x ↗
18. Nunes C. · Pharm. Res. · 2006 · 23 · 239310.1007/s11095-006-9022-5 ↗
19. Suihko E. · Int. J. Pharm. · 2001 · 217 · 22510.1016/S0378-5173(01)00607-X ↗
20. Cardin C. · Acta Crystallogr., Sect. E: Struct. Rep. Online · 2007 · 63 · O317510.1107/S1600536807028267 ↗
21. Ostwald W. · Z. Phys. Chem. · 1900 · 34 · 49510.1515/zpch-1900-3431 ↗
22. Dette S. S. · Chem. Eng. Technol. · 2006 · 29 · 131110.1002/ceat.200600104 ↗
23. Legendre B. · Int. J. Pharm. · 2007 · 343 · 4110.1016/j.ijpharm.2007.04.015 ↗